Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition

This publication has 42 references indexed in Scilit:

• Risk of cardiovascular disease and loss in life expectancy in NAFLD
  Hepatology, 2022
• The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: A systematic review and meta‐analysis
  Neurourology and Urodynamics, 2022
• ChREBP‐driven DNL and PNPLA3 Expression Induced by Liquid Fructose are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High‐Fat Diet‐Fed Rat Model
  Molecular Nutrition & Food Research, 2022
• Deletion of Fructokinase in the Liver or in the Intestine Reveals Differential Effects on Sugar-Induced Metabolic Dysfunction
  Cell Metabolism, 2020
• Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
  Current Atherosclerosis Reports, 2020
• PPARs and nonalcoholic fatty liver disease
  Biochimie, 2017
• Fibrates and cholestasis
  Hepatology, 2015
• IRE1α-XBP1s Induces PDI Expression to Increase MTP Activity for Hepatic VLDL Assembly and Lipid Homeostasis
  Cell Metabolism, 2012
• Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists
  Bioorganic & Medicinal Chemistry Letters, 2007
• Tolerability of fibric acids. comparative data and biochemical bases
  Pharmacological Research, 1992